Delving into the Latest Updates on Guangxi University of Chinese Medicine with Synapse

Overview

Tags

Neoplasms

Immune System Diseases

Endocrinology and Metabolic Disease

Small molecule drug

Herbal medicine

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	4
Immune System Diseases	1
Endocrinology and Metabolic Disease	1
Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

Small molecule drug	4
Herbal medicine	1
Monoclonal antibody	1
Chemical drugs	1

Top 5 Target	Count

NF-κB(Nuclear factor NF-kappa-B complex)	1
PDL1(Programmed death-ligand 1)	1
AKR1C2(aldo-keto reductase family 1 member C2)	1

Background: Acute-on-chronic liver failure (ACLF) is a syndrome characterized by acute deterioration in the setting of chronic liver disease associated with high short-term mortality. Currently, there is no specific treatment for patients with ACLF. Our previous results showed that Chinese herbal medicine (CHM) could reduce the mortality rate and the incidence of complications of ACLF effectively. In this study, we aim to conduct the multi-center randomized controlled trial to evaluate the effect of unified CHM formulas and provide propagable and high-level evidence for clinical practice.
Methods/design: This is a prospective, multicenter, centrally randomized controlled trial. Five hundred and ten patients diagnosed with HBV-related ACLF will be allocated in a 1:1 ratio to SMT group (standard medical therapy) and CHM group (CHM and SMT). The primary outcome is the transplant-free mortality rates at week 4, 8, 12, 24 and 48. Secondary outcomes include (1) the incidence of adverse reactions, (2) influence on liver function, (3) the incidence of serious complications and (4) the level of inflammatory cytokines.
Discussion: The effectiveness and safety of CHM formulas are assessed in the treatment of ACLF.

Start Date10 Jan 2019

Sponsor / Collaborator

Guangxi University of Chinese Medicine

[+7]

ChiCTR-IOR-16008159

/ RecruitingNot ApplicableIIT

A clinical research on the treatment of psoriasis vulgaris with Zhuang medicine medicated thread moxibustion

Start Date10 Apr 2016

Sponsor / Collaborator

Guangxi University of Chinese Medicine

100 Clinical Results associated with Guangxi University of Chinese Medicine

Login to view more data

0 Patents (Medical) associated with Guangxi University of Chinese Medicine

Login to view more data

3,298

Literatures (Medical) associated with Guangxi University of Chinese Medicine

31 Dec 2025·Cancer Biology & Therapy

Upregulation of TTYH3 by lncRNA LUCAT1 through interacting with ALYREF facilitates the metastasis in non-small cell lung cancer

Article

Author: He, Jiaqi ; Jin, Xiaowei ; Zhao, Mei ; Wang, Jiaxiao ; Wang, Changhong ; Meng, Jinming ; Xie, Sheng ; Shi, Wei ; Yang, Chunlei ; Fang, Fang

Metastasis is the predominant culprit of cancer-associated mortality in non-small cell lung cancer (NSCLC). Tweety homolog 3 (TTYH3) reportedly functions vitally in the development of diverse cancers, including NSCLC; nevertheless, its role in NSCLC metastasis remains ambiguous. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) and western blot were initially employed to detect TTYH3 expression in NSCLC and normal lung epithelial cells. Subsequently, A549 and NCI-H1650 cells were chosen as NSCLC models in vitro and transfected with short hairpin RNAs (sh-TTYH3, sh-LUCAT1, and sh-ALYREF) or overexpression plasmids (oe-ALYREF and oe-TTYH3). Transwell assays were used for migrative and invasive tests. Epithelial mesenchymal transformation (EMT)-related proteins (E-cadherin, N-cadherin, Vimentin, and Snail) were measured by western blot. A mouse lung metastasis model was built to define the function of TTYH3 in NSCLC metastasis, followed by hematoxylin-eosin staining. RNA pull-down, RNA immunoprecipitation, qRT-PCR, western blot, and actinomycin D assays were adopted to determine the relationships among LUCAT1, ALYREF, and TTYH3. TTYH3 was highly expressed in NSCLC cells relative to normal lung cells. Functionally, TTYH3 knockdown restrained NSCLC migration, invasion, EMT, and metastasis. Mechanistic experiments demonstrated that LUCAT1 bound to ALYREF. After LUCAT1 knockdown, TTYH3 expression and mRNA stability were reduced, which was reversed by ALYREF overexpression. Furthermore, ALYREF overexpression counteracted the inhibitory effects of LUCAT1 knockdown on NSCLC cell migration, invasion, and EMT. TTYH3 overexpression eliminated the suppressive functions of ALYREF downregulation in NSCLC progression. LUCAT1 promotes TTYH3 expression via interacting with ALYREF, thereby facilitating NSCLC migration, invasion, and EMT.

31 Dec 2025·Renal Failure

Association between weekend catch-up sleep and chronic kidney disease: insights from NHANES 2017–2020

Article

Author: Zhang, Ting ; Gao, Hongjun ; Chen, Sheng ; Zhang, Jianqiang

OBJECTIVEThis study aimed to explore the association between weekend catch-up sleep (WCS) and chronic kidney disease (CKD) in American adults.METHODSUtilizing data from the National Health and Nutrition Examination Survey (NHANES) spanning 2017 to 2020, this study encompassed 4,934 individuals aged 20 years and above. We assessed the risk of CKD in relation to WCS. To evaluate CKD risk across various WCS durations, participants were categorized into four groups based on WCS length: < 1 h (reference group), ≥ 1 h and < 2 h, ≥ 2 h and < 3 h, and ≥ 3 h.RESULTSIn the fully adjusted multivariate logistic regression model, the odds ratio (OR) of CKD to WCS response was 0.86 (95% CI = 0.61-1.22; p = 0.31). In addition, only CKD was significantly associated with WCS duration between 2-3 h (OR = 0.44, 95% CI = 0.21-0.88, p = 0.03). Subgroup analyses showed stronger negative associations (p < 0.05) for men and women with a WCS of 2-3 h, adults under 60 years of age with a WCS of 2-3 h, those with less than 1 h of catch-up sleep on weekends and a body mass index (BMI) of 25-29.9, those with a BMI of less than 25 or greater than or equal to 30 with a WCS of 2-3 h, and those with less than 7 h of sleep on weekdays and 2-3 h of catch-up sleep on weekends.CONCLUSIONOur findings suggest that when weekday sleep duration is < 7 h, WCS in 2-3 h is strongly associated with a lower prevalence of CKD.

31 Dec 2025·Drug Delivery

Reliable high-PAP-1-loaded polymeric micelles for cancer therapy: preparation, characterization, and evaluation of anti-tumor efficacy

Article

Author: Liao, Naikai ; Ye, Fang ; Huang, Longping ; Li, Qi

The mitochondrial potassium channel Kv1.3 is a critical therapeutic target, as its blockade induces cancer cell apoptosis, highlighting its therapeutic potential. PAP-1, a potent and selective membrane-permeant Kv1.3 inhibitor, faces solubility challenges affecting its bioavailability and antitumor efficacy. To circumvent these challenges, we developed a tumor-targeting drug delivery system by encapsulating PAP-1 within pH-responsive mPEG-PAE polymeric micelles. These self-assembled micelles exhibited high entrapment efficiency (91.35%) and drug loading level (8.30%). As pH decreased, the micelles exhibited a significant increase in particle size and zeta potential, accompanied by a surge in PAP-1 release. Molecular simulations revealed that PAE's tertiary amine protonation affected the self-assembly process, modifying hydrophobicity and resulting in larger, loosely packed particles. Furthermore, compared to free PAP-1 or PAP-1 combined with MDR inhibitors, PAP-1-loaded micelles significantly enhanced cytotoxicity and apoptosis induction in Jurkat and B16F10 cells, through mechanisms involving decreased mitochondrial membrane potential and elevated caspase-3 activity. In vivo, while free PAP-1 failed to reduce tumor size in a B16F10 melanoma mouse model, PAP-1-loaded micelles substantially suppressed tumors, reducing volume by up to 94.26%. Fluorescent-marked micelles effectively accumulated in mouse tumors, confirming their targeting efficiency. This strategy holds promise for significantly improving PAP-1's antitumor efficacy in tumor therapy.

100 Deals associated with Guangxi University of Chinese Medicine

Login to view more data

100 Translational Medicine associated with Guangxi University of Chinese Medicine

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 03 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

5

2

Preclinical

IND Approval

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Bawei Longzuan Granules	Rheumatoid Arthritis More	IND Approval
Mogroside	Diabetes Mellitus, Type 2 More	Preclinical
Azadirachta indica leaves extract ( AKR1C2 )	Prostatic Cancer More	Preclinical
CN115197236	Neoplasms More	Discovery
CN117298269 ( PDL1 )	Neoplasms More	Discovery